Holen Sie sich die Stockscreener-App
7.20
0.83%
-0.06
Schlusskurs vom Vortag:
$7.26
Offen:
$7.7548
24-Stunden-Volumen:
5,982
Relative Volume:
0.86
Marktkapitalisierung:
$37.38M
Einnahmen:
$2.61M
Nettoeinkommen (Verlust:
$1.69M
KGV:
23.98
EPS:
0.3003
Netto-Cashflow:
-
1W Leistung:
-4.95%
1M Leistung:
-10.53%
6M Leistung:
-20.09%
1J Leistung:
-23.40%
1-Tages-Spanne:
$7.20
$7.7548
1-Wochen-Bereich:
$7.1297
$7.7548
52-Wochen-Spanne:
$6.55
$10.00
Daxor Corporation Stock (DXR) Company Profile
Firmenname
Daxor Corporation
Sektor
Telefon
212-330-8500
Adresse
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
Vergleichen Sie DXR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
7.20 | 37.38M | 2.61M | 1.69M | 0 | 0.3003 |
|
ISRG
Intuitive Surgical Inc
|
563.95 | 190.13B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
93.25 | 48.17B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BDX
Becton Dickinson Co
|
175.34 | 47.86B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
247.65 | 35.48B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
81.76 | 16.11B | 3.93B | 415.40M | 384.70M | 2.06 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-05-16 | Eingeleitet | Ascendiant Capital Markets | Buy |
Daxor Corporation Aktie (DXR) Neueste Nachrichten
Daxor (DXR) Expands Diagnostic Solutions Across U.S. Healthcare Systems | DXR Stock News - GuruFocus
Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems - GlobeNewswire
Daxor announces opening of new BVA program at Florida center - TipRanks
Daxor (DXR) Launches Advanced BVA Program in Tampa Bay Healthcare Center | DXR Stock News - GuruFocus
Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology - GlobeNewswire
Renaissance Technologies LLC Has $214,000 Stock Holdings in Daxor Co. (NASDAQ:DXR) - Defense World
Daxor announces expansion of BVA capabilities in three new hospitals - TipRanks
Daxor (DXR) Expands Blood Volume Analysis with New Hospital Part - GuruFocus
Daxor (DXR) Expands Blood Volume Analysis with New Hospital Partnerships | DXR Stock News - GuruFocus
Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance - GlobeNewswire
Daxor Expands Blood Volume Analysis Network: 3 Hospitals Choose Zero-Capital Diagnostic Solution - Stock Titan
NeuroMetrix (NASDAQ:NURO) and Daxor (NASDAQ:DXR) Head-To-Head Comparison - Defense World
Daxor Corporation Secures Funding for Blood Volume Analyzer Study - Medical Product Outsourcing
Daxor stock hits 52-week low at $6.83 amid market challenges - MSN
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions - The Manila Times
Daxor Corporation to Exhibit at the 45th International - GlobeNewswire
Revolutionary Blood Volume Analysis: How Daxor's 98% Accurate Tech is Transforming Heart and Lung Care - Stock Titan
Daxor (NASDAQ:DXR) versus Integra LifeSciences (NASDAQ:IART) Head to Head Review - Defense World
(DXR) Trading Report - news.stocktradersdaily.com
Daxor Corporation to Showcase Innovative Blood Volume - GlobeNewswire
Daxor (DXR) to Exhibit at MedAxiom CV Transforum Spring'25 Conference | DXR Stock News - GuruFocus
Daxor to showcase blood volume analysis at Cardiovascular Transforum conference - TipRanks
Revolutionary Blood Volume Technology Slashes Mortality Rates by 82%Groundbreaking Clinical Results Unveiled - Stock Titan
Daxor announces new data at ACC on blood volume analysis - TipRanks
Daxor (DXR) Unveils Promising Heart Failure Study Results at ACC Conference | DXR Stock News - GuruFocus
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic - GlobeNewswire
Breakthrough Heart Failure Study: Daxor BVA Test Doubles Patient Survival Rates - Stock Titan
Daxor (DXR) Submits Next-Gen Blood Analyzer to FDA for Approval - GuruFocus
Daxor submits new blood volume analyzer to FDA By Investing.com - Investing.com South Africa
Daxor Corporation Submits 510(K) To FDA For Next-Generation Blood Volume Analyzer - marketscreener.com
Daxor submits new blood volume analyzer to FDA - Investing.com
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer - GlobeNewswire
Revolutionary Blood Volume Analyzer With Military Backing Advances Toward FDA Green Light - Stock Titan
CEO’s Bold Move: Major Investment in Daxor Stock - TipRanks
Daxor CEO Michael Feldschuh purchases over $16,000 in stock By Investing.com - Investing.com South Africa
Daxor CEO Michael Feldschuh purchases over $16,000 in stock - Investing.com Australia
DAXOR CEO Michael Richard Feldschuh Buys 2,063 Shares - TradingView
Where are the Opportunities in (DXR) - news.stocktradersdaily.com
Daxor Corporation (NASDAQ:DXR) Q4 2024 Earnings Call Transcript - MSN
Daxor (NYSEAMERICAN:DXR) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World
Daxor announces new data from Duke University on BVA at ACC - TipRanks
Daxor’s BVA technology gains traction at cardiology event - Investing.com
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo - GlobeNewswire
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo - The Manila Times
Duke Research Reveals Why Daxor's Blood Test Outperforms Traditional Heart Failure Methods - Stock Titan
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks - GlobeNewswire
Daxor Expands to 3 New Locations in New Jersey, Midwest - MarketScreener
Breakthrough Blood Volume Tech With 98% Accuracy Gains Major Healthcare Adoption - Stock Titan
Daxor CEO Michael Feldschuh purchases $8,130 in company shares - Investing.com
Daxor CEO Michael Feldschuh purchases $8,130 in company shares By Investing.com - Investing.com UK
Daxor CEO Feldschuh buys shares worth $5,273 By Investing.com - Investing.com Canada
Finanzdaten der Daxor Corporation-Aktie (DXR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.71%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):